Establishment of reference intervals for osteoarthritis related biomarkers – the FNIH/OARSI OA biomarkers consortium

Kraus, Virginia B.; Hargrove, David; Hunter, David J.; Renner, Jordan B.; Jordan, Joanne M.

doi:10.1016/j.joca.2014.02.103

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, this weak correlation may be accounted by the fact that in our study we looked at regions of interest in one joint only whereas CH exerts an effect on all the joints which is consequently reflected by the concentration of PIIANP and CS846 in blood. Reference values of serum concentrations of PIIANP and CS846 in healthy subjects have been published [ 9 ] . Nevertheless, it is difficult to compare our data with those reference data, as the serum samples had been stored for up to 5 years.…”

Section: Discussionmentioning

confidence: 99%

“…This study maps into the larger aim of identifying biochemical and imaging biomarkers for OA. For example, one of the objectives of the epidemiological study that is presently carried out by the Osteoarthritis Initiative [ 9 ] is to correlate imaging with chemical biomarker data in patients with OA. The results of that study, comprising 4,796 subjects, in that regard, i.e.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited

et al. 2017

View full text Add to dashboard Cite

To evaluate in an interventional trial on knee osteoarthritis (OA) the level and change of two serum biomarkers and their correlation with imaging parameters. The previously reported interventional OA study (ClinicalTrials.gov: NCT00536302) identified a positive effect of collagen hydrolysate (CH) on cartilage morphology in patients with knee OA using delayed gadolinium enhanced magnetic resonance imaging (dGEMRIC). It was the objective in this research project to evaluate in an interventional clinical trial on knee OA the level and change of two serum biomarkers and their correlation with imaging parameters. In blood samples of study participants, we determined the concentration of procollagen type II N-terminal propeptide (PIIANP) and aggrecan chondroitin sulfate 846 epitope (CS846) at baseline (BL) and at the follow-up (FU) visits at 24 and 48 weeks. We measured the level and change of biomarker concentrations in both study groups, and the correlation of those changes with changes in dGEMRIC. For the biomarker PIIANP, we observed a significantly greater increase in the CH group (29.9% vs. 1.2% at week 24, P = 0.001). For CS846, the mean concentration was lower among the CH treated participants at 24 weeks (78% vs. 96%, P = 0.045). Consistent correlations of changes in biomarkers PIIANP and CS846 with changes of the dGEMRIC score could not be observed. In this study, different changes per treatment group, CH and placebo were seen for dGEMRIC and PIIANP BL to 24 weeks FU, but only weak correlations between changes in dGEMRIC and biochemical markers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited

et al. 2017

View full text Add to dashboard Cite

show abstract

Osteoarthritis: Current Molecular Biomarkers and the Way Forward

Kraus

Karsdal

2020

Calcif Tissue Int

View full text Add to dashboard Cite

Osteoarthritis Year in Review 2014: we need more biochemical biomarkers in qualification phase

Blanco

2014

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

The current diagnosis of osteoarthritis (OA) relies on the description of pain symptoms, affected joint stiffness, and radiography used as the reference technique for determining the grade of joint destruction. Limitations of the presently available diagnostic tests have provided an impetus for the substantial increase in interest in finding new specific biological markers for cartilage degradation to facilitate the early diagnosis of joint destruction, evaluate disease progression and improve disease prognosis. Biomarkers for OA are also useful for drug development, treatment monitoring, and as a basis for personalized evidence-based action plans. This review summarizes 29 manuscripts published during 2013 with a focus on soluble biochemical biomarkers, primarily those utilizing proteomic, metabolomics, lipidomic and imaging mass spectrometry technologies.

show abstract

Establishment of reference intervals for osteoarthritis related biomarkers – the FNIH/OARSI OA biomarkers consortium

Cited by 4 publications

References 0 publications

Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited

Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited

Osteoarthritis: Current Molecular Biomarkers and the Way Forward

Osteoarthritis Year in Review 2014: we need more biochemical biomarkers in qualification phase

Contact Info

Product

Resources

About